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Background-—Mortality for infants with single ventricle congenital heart disease remains as high as 8% to 12% during the
interstage period, the time between discharge after the Norwood procedure and before the stage II palliation. The objective of our
study was to determine the association between digoxin use and interstage mortality in these infants.
Methods and Results-—We conducted a retrospective cohort study using the Pediatric Heart Network Single Ventricle
Reconstruction Trial public use dataset, which includes data on infants with single right ventricle congenital heart disease
randomized to receive either a Blalock-Taussig shunt or right ventricle-to-pulmonary artery shunt during the Norwood procedure at
15 institutions in North America from 2005 to 2008. Parametric survival models were used to compare the risk of interstage
mortality between those discharged to home on digoxin versus those discharged to home not on digoxin, adjusting for center
volume, ascending aorta diameter, shunt type, and socioeconomic status. Of the 330 infants eligible for this study, 102 (31%) were
discharged home on digoxin. Interstage mortality for those not on digoxin was 12.3%, compared to 2.9% among those on digoxin,
with an adjusted hazard ratio of 3.5 (95% CI, 1.1–11.7; P=0.04). The number needed to treat to prevent 1 death was 11 patients.
There were no differences in complications between the 2 groups during the interstage period.
Conclusions-—Digoxin use in infants with single ventricle congenital heart disease is associated with significantly reduced
interstage mortality. ( J Am Heart Assoc. 2016;5:e002566 doi: 10.1161/JAHA.115.002566)
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A lthough great strides have been made in the surgical andmedical management of infants with single ventricle
congenital heart disease, early mortality remains high. In the
last decade, postoperative in-hospital mortality after the
Norwood procedure has ranged from 7% to 19%, and mortality
before the stage II palliation among those discharged to home
after the Norwood procedure has ranged from 2% to 12%.1–6
This interstage period, the time between discharge to home
after the Norwood procedure and the stage II operation, has
been the focus of many efforts to reduce mortality. The
effects of altering surgical options, such as use of the hybrid
procedure7 and closer monitoring of infants with the use of
home oxygen saturation or weight monitoring on interstage
mortality, have been reported on.8 Though initial results have
been promising, particularly in single-center studies, sustain-
ability of improved interstage mortality has not been demon-
strated in multicenter studies.
Digoxin was traditionally a mainstay of treatment for heart
failure (HF) in children.9–13 Over the last 2 decades, however,
digoxin has lost favor with many pediatric cardiologists, with
only 28% of patients in the National Pediatric Cardiology Quality
Improvement Collaborative (NPC-QIC) discharged home on the
medicine.14 Reasons for the decreased use of digoxin include
question about its mechanism of action, concerns about
toxicity, and availability of other pharmacological options.15
However, it has recently been suggested that digoxin might
play a role in reducing interstage mortality.16
The objective of our study was to evaluate the association
of outpatient digoxin use with interstage mortality in infants
with single ventricle congenital heart disease in a multicenter
study using data from the Pediatric Heart Network Single
Ventricle Reconstruction (SVR) trial. We hypothesized that the
use of digoxin would be associated with reduced interstage
mortality.
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Methods
Data Source and Study Design
We performed a retrospective cohort study using data from
the Pediatric Heart Network SVR Trial public use dataset
(available at http://www.pediatricheartnetwork.org/For
Researchers/PHNPublicUseDatasets.aspx). The SVR trial
has previously been well described.17 Briefly, the SVR trial
enrolled infants in 2005–2008 with single ventricle congen-
ital heart disease with a dominant morphologically right
ventricle with the purpose of comparing outcomes for the
Norwood procedure with the modified Blalock-Taussig shunt
(MBTS) versus the right ventricle-to-pulmonary artery shunt
(RVPAS). Infants were randomized to either of the 2 surgical
treatment options and followed until 14 months of age.
Institutional review board approval and informed consent
were obtained at participating institutions for the initial trial,
and the public use dataset contains no personally identifiable
information.
For our study, the primary aim was to compare the
interstage mortality for infants in the SVR trial for those who
were discharged to home on digoxin compared to those
discharged to home without digoxin. Interstage mortality was
defined as death before stage II palliation. The inclusion
criterion was any patient discharged to home after the
Norwood procedure before stage II palliation. In order to avoid
the potential confounder for mortality attributable to arrhyth-
mia, which may be collinear with digoxin treatment, we
excluded all infants with a history of arrhythmia during their
Norwood hospitalization. In the SVR trial, arrhythmias that
required medication or other treatment during the Norwood
hospitalization were recorded; these included atrial fibrillation,
atrial flutter, supraventricular tachycardia, junctional ectopic
tachycardia, ventricular tachycardia, and second- or third-
degree atrioventricular block. The secondary aim was to
compare the occurrence of complications during the inter-
stage period amongst the 2 groups.
Statistical Analysis
Descriptive statistics were calculated for all variables of
interest and include medians and ranges or counts and
percentages, when appropriate. Demographics and clinical
characteristics (pre-Norwood, during Norwood hospitalization,
and after discharge for Norwood) were compared between
patients on digoxin at Norwood discharge to those not on
digoxin at discharge. Comparisons were made using chi-
square tests for categorical variables and Wilcoxon rank-sum
tests for continuous variables. When expected cell counts
were small (<5), an exact test was used in place of the chi-
square test. The majority of patients died or received their
stage II surgery within 6 months of their Norwood surgery,
with less than 13% of the original sample size remaining at
risk at 7 months. As a result, survival estimates were based
on 6 months after Norwood surgery.
The time-dependent outcome of interstage mortality after
Norwood was parametrically modeled. Parametric probability
estimates for the time-dependent outcome were derived from
a model based on multiple, overlapping phases of risk
(available for use with the SAS system at https://www.
lerner.ccf.org/qhs/software/hazard/documents/hazard.pdf).
The HAZARD procedure uses maximum likelihood estimates
to resolve risk distribution of time to event in up to 3 phases
of risk (early, constant, and late). For the outcome of
interstage mortality, an early-phase model best described
the data, given that the vast majority of the deaths occurred
within 2 to 3 months after the Norwood procedure.
Variables potentially influencing the likelihood of inter-
stage mortality and included in the adjusted model were
chosen a priori from demographic and clinical variables
previously identified in the literature, namely: center volume
(enrolled <20 patients in SVR trial vs ≥20 patients);
ascending aorta diameter (<0.3 cm preoperative measure-
ment vs ≥0.3 cm); shunt type (MBTS vs RVPAS); and
socioeconomic status (census block poverty level, as a
continuous variable).2 Before multivariable modeling, mean
imputation was used to reduce list-wise deletion of patients
with missing data. Mean imputation was used only when
data were missing at random, and provided that no more
than 5% of the data for a specific variable were missing (ie,
for socioeconomic status only). Effects of digoxin use on the
probability of interstage mortality are given as a hazard ratio
(HR) with an associated 95% CI. Statistical analyses were
performed using SAS software (version 9.4; SAS Institute
Inc., Cary, NC), and statistical significance was assessed at
the 0.05 level.
We performed additional analyses to examine the impact
of some of our assumptions on our results. First, though the
HAZARD procedure in SAS allows us to parametrically model
early hazard of mortality, it does not allow for modeling of
random effects such as individual center. Therefore, to
examine the possible influence of clustering of patients
within centers, we further compared the estimate for the
effect of digoxin on interstage mortality using a shared frailty
model with PHREG treating center effects as independent and
identically distributed random variables. Second, to assess
the impact that removing children with a history of arrhythmia
may have had on our findings, we performed a sensitivity
analysis using our multivariate model in which we (1) analyzed
the association of digoxin with mortality in only those with
tachyarrhythmia and (2) analyzed the association of digoxin
with mortality in all patients, both those without any
arrhythmia and those with any tachyarrhythmia. For these
sensitivity analyses, we excluded those with a history of
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second- or third-degree atrioventricular block, given that
digoxin would be contraindicated in this population.
Results
Of 549 patients in the SVR trial, 330 met inclusion criteria for
this study (Figure 1). Of these, 102 (31%) were discharged to
home on digoxin after the Norwood procedure. Those
discharged home on digoxin did not differ from those not
on digoxin with regard to demographic, preoperative, or
operative characteristics, but those discharged home on
digoxin were more likely to have longer length of stay after the
Norwood procedure and were more likely to be of a younger
age at the time of stage II palliation (Table 1). There was wide
variation with regard to use of digoxin by center, with use of
digoxin at discharge ranging from 0% to 100% (Table 2). Of
the 12 centers that discharged more than 0%, but less than
100%, of infants home on digoxin, interstage mortality was
lower in the digoxin group at 10 centers.
Overall, interstage mortality was significantly different
between the 2 groups, with 28 of 228 (12.3%) of those not on
digoxin dying before stage II palliation compared to 3 of 102
(2.9%) of those on digoxin (Figure 2). With an absolute risk
reduction of 9.4%, the number needed to treat (1/absolute
risk reduction) in order to prevent 1 interstage death in this
population is 11 patients. After adjusting for center volume,
ascending aorta diameter, shunt type, and socioeconomic
status, those not on digoxin had an HR for interstage mortality
of 3.5 (95% CI, 1.1–11.7; P=0.04) compared to those on
digoxin (Table 3).
Our additional analyses yielded similar results to this
primary analysis. In the shared frailty model with center as a
random effect, the estimated hazard of mortality in those not
on digoxin was 3.8 times that of those that were on digoxin
(95% CI, 1.1–12.8; P=0.03). Moreover, the random effect for
center was not statistically significant (P=0.15). In examina-
tion of the patients excluded on account of an arrhythmia, 91
had a tachyarrhythmia and survived to hospital discharge
after the Norwood procedure. Of these, 50 were discharged to
home on digoxin. Interstage mortality in the group not on
digoxin was 17.1% (7 of 41) compared to 8.0% (4 of 50) for
the group on digoxin (HR, 2.4; 95% CI, 0.7–8.3; P=0.17). When
adding these patients to the original analyses, the overall
estimated hazard for mortality for the group not on digoxin
was 3.2 times that of the group on digoxin (95% CI, 1.4–7.2;
P=0.005).
Overall, 52% of children experienced an adverse event
during the interstage period. In the digoxin group, 56 of the
102 children experienced a total of 111 complications;
among the children not on digoxin, 116 of the 228 infants
had a total of 242 complications. There were no significant
differences in the number of complications among any
category (Table 4).
Discussion
In this large, multicenter cohort study of infants with single
right ventricle congenital heart disease, we found the use of
digoxin to be associated with significantly reduced interstage
mortality. Those subjects not discharged on digoxin had a
more than 3-fold higher hazard of interstage mortality as
compared to those prescribed the drug. For every 11 children
treated with digoxin, 1 interstage death would be prevented.
Given this potential benefit and the lack of difference between
significant adverse events observed between the 2 cohorts,
the routine use of digoxin should be considered during the
interstage period.
Our findings are in agreement with the only other
multicenter study, to our knowledge, to examine the associ-
ation of digoxin with interstage mortality. In a study using data
from the NPC-QIC in June 2008 to July 2013, Brown et al.
found that not being on digoxin at the time of discharge after
the Norwood procedure conferred an increase in the absolute
risk of interstage mortality of 11% and an adjusted odds ratio
for interstage mortality of 2.9.16 We found similar results in
our study, but by using survival analysis methods instead of
logistic regression, our study accounted for the fact that there
are varying durations of time at risk for each individual.
Nevertheless, the fact that 2 separate independent multicen-
ter studies with different time periods (minimal overlap of
6 months, during which the NPC-QIC enrolled fewer than 10
patients) found similar results with similar effect sizes lends
credence to the finding that digoxin may bestow a protective
Figure 1. Selection criteria. All patients enrolled in the Pediatric
Heart Network Single Ventricle Reconstruction Trial were eligible
for enrollment. Those who had a history of arrhythmia during
hospitalization for the Norwood procedure, who did not survive to
hospital discharge, or who remained in the hospital until their
stage II operation were excluded.
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Table 1. Demographics of Digoxin vs No Dgoxin Groups
Patient Characteristics
Digoxin (N=102) No Digoxin (N=228)
P ValueN (%) or Median (IQR) N (%) or Median (IQR)
Sex, male 66 (64.7) 145 (63.6) 0.85
Race
White 82 (80.4) 175 (76.8) 0.46
Nonwhite 20 (19.6) 53 (23.2)
Hispanic 23 (22.5) 46 (20.4) 0.67
Birthweight, kg 3.07 (2.80–3.45) 3.20 (2.78–3.50) 0.51
Gestational age, weeks 39 (38–39) 38 (38–39) 0.58
Aortic atresia at screening 64 (62.7) 148 (64.9) 0.70
Age at Norwood, days 6 (4–8) 6 (4–8) 0.59
Norwood perfusion type
DHCA only 57 (56.4) 131 (58.0)
RCP only or RCP/DHCA time ≤10 min 25 (24.8) 51 (22.5%) 0.91
DHCA and RCP time >10 min 19 (18.8) 44 (19.5)
Number of complications post-Norwood 2.0 (1.0–4.0) 2.0 (1.0–5.0) 0.85
Syndrome or genetic anomaly 26 (31.3) 52 (30.8) 0.93
Shunt type at end of Norwood
MBTS 44 (43.1) 102 (44.7) 0.79
RVPAS 58 (56.9) 126 (55.3)
Not on oral feeds at Norwood discharge 21 (20.6) 53 (23.3) 0.58
AVVR grade PRE Norwood
Mild/none 88 (86.3) 203 (89.0) 0.47
Moderate/severe 14 (13.7) 25 (11.0)
AVVR grade POST Norwood
Mild/none 80 (78.4) 184 (80.7) 0.63
Moderate/severe 22 (21.6) 44 (19.3)
Right ventricular fractional area change POST
Norwood, N=314
0.36 (0.32–0.41) 0.36 (0.32–0.41) 0.60
Pre Norwood ascending aorta diameter, cm
<0.3 45 (45.5) 121 (54.3) 0.14
≥0.3 54 (54.5) 102 (45.7)
Mitral valve or aortic Aatresia at baseline 54 (52.9) 121 (53.3) 0.95
Census block poverty level (%) 8.3 (3.1–17.1) 8.9 (4.8–17.1) 0.14
Oxygen saturation at discharge 82 (80–85) 83 (80–86) 0.15
Postoperative length of stay, days 26 (19–40) 21 (15–33) 0.005*
Age at stage II palliation, days, N=289 148 (120–187) 163 (137–195) 0.005*
Center volume
Small (<20 patients) 18 (17.6) 60 (26.3) 0.09
Large (≥20 patients) 84 (82.4) 168 (73.7)
AVVR indicates atrioventricular valve regurgitation; DHCA, deep hypothermic circulatory arrest; MBTS, modified Blalock-Taussig shunt; RCP, regional cerebral perfusion; RVPAS, right
ventricle-to-pulmonary artery shunt.
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effect against interstage mortality for infants with single
ventricle congenital heart disease.18
If digoxin may have such important effects on improving
cardiac function and hemodynamics, why then is it not more
commonly prescribed? Indeed, digoxin, the oldest drug
available for treatment of HF, was formerly the mainstay of
treatment for HF in both adults and children given its supposed
effects on inotropy, chronotropy, and the sympathetic nervous
system, although its demonstration in laboratory studies did
not always translate to clinical improvement.19–23 However, in
1997, the Digitalis Investigation Group conducted a random-
ized, placebo-controlled trial of 7800 adults and found no
improvement in mortality.24 Digoxin use subsequently declined
both among adults and children.25 With no proven benefit and
concerns about toxicity, many advocated against its use in
children.26
Episodes of digoxin toxicity were observed neither in our
study nor in a recent randomized, double-blind, multicenter
study comparing the use of digoxin versus propranolol for
treatment of supraventricular tachycardia.27 However, the risk
of digoxin toxicity should not be ignored, particularly given
that there is a decreased clearance of digoxin in children as
compared to adults.28,29 Although rare, digoxin toxicity is a
well-recognized entity in children, characterized by nausea,
vomiting, anorexia, weakness, and atrioventricular block.10,30
There are important limitations to our study. First, this was
an observational study and participants were not randomized
to receive digoxin. Whereas a randomized control trial would
be ideal, this may not be feasible. With a recent baseline
interstage mortality rate of 8%,31 a study would need to enroll
1000 infants with single ventricle who survived to Norwood
discharge in order to have 80% power to detect a difference of
10% interstage mortality in the no digoxin group versus 5% in
the digoxin group. Second, our analyses were all intention to
treat. Though we know whether kids were discharged from
the hospital to home on digoxin after the Norwood procedure,
we do not know whether those on digoxin took the medicine
or were continued on the medicine, nor do we know whether
those not discharged to home on the medicine were later
prescribed it as an outpatient. Regardless, the approach that
we used did reflect real-world conditions, and our findings can
be used to dictate decision making at the time of discharge
after the Norwood procedure. Third, we do not know what
Table 2. Percent of Infants Discharged to Home on Digoxin
and Interstage Mortality by Center
Center % on Digoxin
Interstage Mortality (%)
On Digoxin NOT on Digoxin
A 0.0 N/A 40.0
B 5.6 0 11.8
C 8.3 0 9.1
D 15.8 0 6.3
E 16.1 0 5.8
F 19.4 0 13.8
G 21.4 0 21.2
H 21.7 20 27.8
I 22.7 0 5.9
J 28.6 0 20.0
K 33.3 0 16.7
L 65.0 3.9 0
M 81.5 4.6 0
N 100.0 0 N/A
O 100.0 0 N/A
N/A indicates not applicable.
Figure 2. Parametric survival curve. This survival curves shows
the interstage mortality for infants discharged to home after the
Norwood procedure from 2005 to 2008 in the Pediatric Heart
Network Single Ventricle Reconstruction Trial. Patients were
censored at the time of the stage II operation or at 6 months of
age, whichever occurred earlier. Those discharged to home not on
digoxin had significantly higher mortality than those on digoxin
(P=0.02). After adjusting for center volume, ascending aorta
diameter, shunt type, and socioeconomic status, those not on
digoxin had a hazard ratio for interstage mortality of 3.5 (95% CI,
1.1–11.7; P=0.04) compared to those on digoxin.




















*Adjusted for center volume, ascending aorta diameter, shunt type, and socioeconomic
status.
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dosing regimen was used. The recommended dosing regimen
for infants 1 month to 2 years of age is 10 to 15 lg/kg/day,
although lower dosing may be needed for treatment of HF.15
Future research into the optimal dosing regimen for children
during the interstage period is still needed. Finally, we do not
have information regarding an indication for why a child was
on digoxin. We excluded all children with a history of
arrhythmia in our initial analyses, and children with single
ventricle congenital heart disease typically have some degree
of HF.21 In our experience, the choice of whether to treat a
child with digoxin is driven by physician preference, but it may
be possible that children treated with digoxin had some
unmeasured variable that influenced the decision to treat
them. We attempted to control for such factors, including
effects of surgical center, and found no such associations in
our study. Furthermore, we found similar effect sizes for
digoxin in patients both with and without arrhythmia. Of note,
if the choice was made to treat these children because they
were felt to be in more-severe HF and digoxin were to have no
effect on mortality, one would expect their outcomes to be
worse, not better.
Conclusions
In the Pediatric Heart Network SVR trial, infants with single
right ventricle congenital heart disease who were not
prescribed digoxin upon discharge after the Norwood proce-
dure had greater than 3 times the hazards of interstage
mortality as compared to those prescribed digoxin.
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